TORONTO, January 30, 2019
3D Signatures Inc. (TSX-V:DXD) (the “Company” or “3DS“) proposes to consolidate its issued and outstanding common share capital and changes its name in connection with the share consolidation.
In the special shareholders meeting scheduled for February 28, 2019 the Company’s shareholders will be asked to vote on the consolidation of the Company’s issued and outstanding common shares on the basis of five (5) pre-consolidation shares for one (1) post-consolidation share.
3DS currently has 66,531,545 issued and outstanding common shares. Upon completion of the consolidation the number of post-consolidation common shares would be 13,306,309. No fractional post-consolidation common shares will be issued and no cash will be paid in lieu of fractional post-consolidation common shares. In addition, the Company proposes to change its name in connection with the consolidation to “Telo Genomics Corp”.
The Company’s Board of Directors has determined that share consolidation and name change may assist the Company in obtaining the financing needed to execute on its strategic objectives and allow overcoming barriers of threshold share prices limiting brokerage or institutional investors ability to invest or recommend investments in the Company’s common shares. This will have the potential to allow the Company to raise sufficient levels of funding at reasonable dilution levels to support robust programs to create value for shareholders within reasonable timeframes.
The share consolidation and name change are subject to shareholders approval at the special meeting of shareholders to be held on February 28, 2019, in addition to the approval of the TSX Venture Exchange.
3DS (TSX-V:DXD) is a personalized medicine company with a proprietary software platform, TeloViewTM, that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS’ TeloViewTM software platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug’s efficacy and toxicity. 3DS’ proprietary software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual’s disease based on their unique TeloViewTM score. As healthcare moves increasingly toward better informed, patient-centric approaches, the Company intends for the TeloViewTM platform to deliver personalized medicine that allows for better treatments, leading to better outcomes.
The TeloViewTM platform is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer’s disease. 3DS benefits from twenty years of research, $25M of non-dilutive investment into its platform and more than 130 supporting publications and holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including (but not limited to) hematological disorders such as Hodgkin’s lymphoma, multiple myeloma, and chronic myeloid leukemia. 3DS’ intellectual property portfolio also covers prostate cancer, breast cancer, lung cancer, melanoma, colorectal cancer, and Alzheimer disease.
For more information, visit the Company’s website at: http://www.3dsignatures.com.
For further information, please contact:
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto ON, M5G 1L7
TSX Venture Exchange Disclaimer
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, “will”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding access to funding, collaboration and commercial opportunities, the Company’s assessment of current and future clinical programs, and efficacy and success of the TeloViewTM platform are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.